The FDA has approved an inhaled, rapid-acting, dry-powder formulation of recombinant human insulin (Afrezza–Mannkind/Sanofi) for treatment of adults with type 1 or type 2 diabetes. In patients with type 1 diabetes, the drug must be used in combination with long-acting insulin. Another inhaled, rapid-acting insulin (Exubera) was approved in 2006 for the same indication, but was withdrawn from the market the following year.1
An Inhaled Insulin (Afrezza). JAMA. 2015;313(21):2176–2177. doi:10.1001/jama.2015.5634
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: